UCB - Current Liabilities


UCB reported EUR4.4B in Current Liabilities for its fiscal semester ending in December of 2025.





Current Liabilities Change Date
Alcon AG USD 3B 45M Mar/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bayer EUR 33.46B 875M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
GlaxoSmithKline GBP 21.53B 895M Jun/2026
GRIFOLS EUR 2.24B 112M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 9.35B 307M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Orion EUR 454.5M 344.1M Jun/2026
Recordati EUR 1.4B 30.88M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
UCB EUR 4.4B 470M Dec/2025
Unibail Rodamco EUR 3.13B 2.32B Dec/2025